Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature

ConclusionOur cases show that vemurafenib/cobimetinib treatment is effective inBRAF V600-mutated thyroid carcinoma, also when administered via a feeding tube. Although serious side effects occurred in both patients, we hypothesize that this was not attributable to the administration route. Therefore, administration of vemurafenib/cobimetinib by feeding tube is feasible and effective.Trial registrationClinical trial identification: NCT02925234.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research